Results Round-Up: Big Pharma Grapples With China Slowdown
This article was originally published in Scrip
If there was one overall signal to come out of multinationals' second quarter results, it was that China can no longer be relied upon to be the major driver of growth in emerging markets that it once was, as sales increases are slowing as a result of cost control policies and generic competition. But while several pharma firms' growth in this market fell into single digits in the quarter, the longer term prospects are still seen as positive given strong underlying fundamentals.
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.